Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective - Takeaways - MDSpire

Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective

  • By

  • Lan Jiang

  • Jing Wang

  • Shihong Xiong

  • Sumei Min

  • Na Gong

  • July 10, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors (ICIs) can induce renal injury and multi-organ immune-related adverse events (irAEs), complicating clinical management.

  • 2

    Acute kidney injury, particularly acute tubulointerstitial nephritis, occurs in 2-5% of patients on anti-PD-1/PD-L1 monotherapy.

  • 3

    The predominant renal lesion associated with ICIs is acute tubulointerstitial nephritis, often accompanied by multi-organ involvement.

  • 4

    Mechanistic studies indicate that PD-1/PD-L1 pathway disruption and immune cell heterogeneity are central to ICI-related renal injuries.

  • 5

    The review highlights the need for integrated analysis of ICI-associated renal and multi-organ injury to inform future therapeutic strategies.

Original Source(s)

Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective

  • by Lan Jiang, Jing Wang, Shihong Xiong, Sumei Min, Na Gong

  • July 10, 2026

Related Content

A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer

An integrative naturopathic oncology approach in metastatic malignant melanoma: two case reports

Efficacy and safety of neoadjuvant chemotherapy with immunotherapy versus chemotherapy alone in esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials